Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Cerilliant
Medtronic
McKinsey
Queensland Health
Moodys
Federal Trade Commission
Argus Health

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,919,373

« Back to Dashboard

Which drugs does patent 6,919,373 protect, and when does it expire?

Patent 6,919,373 protects CONCERTA and is included in one NDA.

Protection for CONCERTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-eight patent family members in seventeen countries.
Summary for Patent: 6,919,373
Title: Methods and devices for providing prolonged drug therapy
Abstract:Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
Inventor(s): Lam; Andrew C. (South San Francisco, CA), Shivanand; Padmaja (Mountain View, CA), Ayer; Atul D. (Palo Alto, CA), Weyers; Richard G. (Los Altos, CA), Gupta; Suneel K. (Sunnyvale, CA), Guinta; Diane R. (Palo Alto, CA), Christopher; Carol A. (Belmont, CA), Saks; Samuel R. (Burlingame, CA), Hamel; Lawrence G. (Mountain View, CA), Wright; Jeri D. (Dublin, CA), Hatamkhany; Zahedeh (San Jose, CA)
Assignee: Alza Corporation (Mountain View, CA)
Application Number:09/253,317
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 6,919,373

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-001 Aug 1, 2000 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-004 Apr 1, 2002 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-002 Aug 1, 2000 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-003 Dec 8, 2000 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,919,373

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,548,610 Method and apparatus for reducing static charges during polymerization of olefin polymers ➤ Try a Free Trial
6,905,654 Method and apparatus for reducing static charges during polymerization of olefin polymers ➤ Try a Free Trial
6,930,129 Methods and devices for providing prolonged drug therapy ➤ Try a Free Trial
2,015,125,493 ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,919,373

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 277594 ➤ Try a Free Trial
Austria 321529 ➤ Try a Free Trial
Austria 325606 ➤ Try a Free Trial
Australia 4319799 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Argus Health
McKesson
McKinsey
Federal Trade Commission
Cipla
Chubb
Express Scripts
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.